Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
20.07
-0.08 (-0.40%)
At close: Mar 6, 2026, 4:00 PM EST
20.38
+0.31 (1.54%)
After-hours: Mar 6, 2026, 6:14 PM EST
Apellis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1,004 | 781.37 | 396.59 | 75.42 | 66.56 | |
| Revenue Growth (YoY) | 28.46% | 97.02% | 425.83% | 13.31% | -73.44% | |
| Cost of Revenue | 398.09 | 445.29 | 412.9 | 392.87 | 426.07 | |
| Gross Profit | 605.69 | 336.07 | -16.31 | -317.45 | -359.51 | |
| Selling, General & Admin | 550.27 | 501.05 | 500.82 | 277.16 | 176.77 | |
| Operating Expenses | 550.27 | 501.05 | 500.82 | 277.16 | 176.77 | |
| Operating Income | 55.43 | -164.98 | -517.12 | -594.61 | -536.28 | |
| Interest Expense | -44.33 | -40.39 | -29.58 | -32.63 | -13.24 | |
| Interest & Investment Income | 13.14 | 12.77 | 20.93 | 8.91 | 0.42 | |
| Other Non Operating Income (Expenses) | -0.13 | -2.17 | -0.73 | -0.29 | -96.31 | |
| EBT Excluding Unusual Items | 24.11 | -194.77 | -526.5 | -618.61 | -645.41 | |
| Other Unusual Items | - | -1.95 | - | -32.89 | -100.59 | |
| Pretax Income | 24.11 | -196.72 | -526.5 | -651.5 | -746 | |
| Income Tax Expense | 1.72 | 1.16 | 2.13 | 0.67 | 0.35 | |
| Net Income | 22.39 | -197.88 | -528.63 | -652.17 | -746.35 | |
| Net Income to Common | 22.39 | -197.88 | -528.63 | -652.17 | -746.35 | |
| Shares Outstanding (Basic) | 126 | 124 | 119 | 106 | 84 | |
| Shares Outstanding (Diluted) | 130 | 124 | 119 | 106 | 84 | |
| Shares Change (YoY) | 4.80% | 4.40% | 11.84% | 25.70% | 12.32% | |
| EPS (Basic) | 0.18 | -1.60 | -4.45 | -6.15 | -8.84 | |
| EPS (Diluted) | 0.17 | -1.60 | -4.45 | -6.15 | -8.84 | |
| Free Cash Flow | 45.01 | -88.27 | -595.51 | -515.27 | -564.23 | |
| Free Cash Flow Per Share | 0.35 | -0.71 | -5.02 | -4.86 | -6.68 | |
| Gross Margin | 60.34% | 43.01% | -4.11% | - | - | |
| Operating Margin | 5.52% | -21.11% | -130.39% | -788.38% | -805.67% | |
| Profit Margin | 2.23% | -25.32% | -133.29% | -864.70% | -1121.28% | |
| Free Cash Flow Margin | 4.48% | -11.30% | -150.16% | -683.18% | -847.66% | |
| EBITDA | 56.99 | -163.18 | -515.34 | -593.06 | -534.9 | |
| EBITDA Margin | 5.68% | -20.88% | -129.94% | - | - | |
| D&A For EBITDA | 1.56 | 1.8 | 1.78 | 1.55 | 1.38 | |
| EBIT | 55.43 | -164.98 | -517.12 | -594.61 | -536.28 | |
| EBIT Margin | 5.52% | -21.11% | -130.39% | - | - | |
| Effective Tax Rate | 7.14% | - | - | - | - | |
| Revenue as Reported | 1,004 | 781.37 | 396.59 | 75.42 | 66.56 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.